Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Sci ; 197: 106768, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38643940

ABSTRACT

The negative coordination of growth hormone secretagogue receptor (GHS-R) and growth hormone-releasing hormone receptor (GHRH-R) involves in the repair processes of cellular injury. The allosteric U- or H-like modified GHRH dimer Grinodin and 2Y were comparatively evaluated in normal Kunming mice and hamster infertility models induced by CPA treatment. 1-3-9 µg of Grinodin or 2Y per hamster stem-cell-exhaustion model was subcutaneously administered once a week, respectively inducing 75-69-46 or 45-13-50 % of birth rates. In comparison, the similar mole of human menopausal gonadotropin (hMG) or human growth hormone (hGH) was administered once a day but caused just 25 or 20 % of birth rates. Grinodin induced more big ovarian follicles and corpora lutea than 2Y, hMG, hGH. The hMG-treated group was observed many distorted interstitial cells and more connective tissues and the hGH-treated group had few ovarian follicles. 2Y had a plasma lifetime of 21 days and higher GH release in mice, inducing lower birth rate and stronger individual specificity in reproduction as well as only promoting the proliferation of mesenchymal-stem-cells (MSCs) in the models. In comparison, Grinodin had a plasma lifetime of 30 days and much lower GH release in mice. It significantly promoted the proliferation and activation of ovarian MSCs together with the development of follicles in the models by increasing Ki67 and GHS-R expressions, and decreasing GHRH-R expression in a dose-dependent manner. However, the high GH and excessive estrogen levels in the models showed a dose-dependent reduction in fertility. Therefore, unlike 2Y, the low dose of Grinodin specifically shows low GHS-R and high GHRH-R expressions thus evades GH and estrogen release and improves functions of organs, resulting in an increase of fertility.


Subject(s)
Cell Proliferation , Mesenchymal Stem Cells , Ovary , Female , Animals , Mice , Cell Proliferation/drug effects , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/metabolism , Ovary/drug effects , Ovary/metabolism , Growth Hormone-Releasing Hormone/metabolism , Fertility/drug effects , Receptors, Neuropeptide/metabolism , Humans , Allosteric Regulation/drug effects , Receptors, Ghrelin/metabolism , Cricetinae , Receptors, Pituitary Hormone-Regulating Hormone/metabolism , Dimerization
2.
Korean J Physiol Pharmacol ; 23(1): 89, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30627014

ABSTRACT

[This corrects the article on p. 637 in vol. 22, PMID: 30402024.].

3.
Korean J Physiol Pharmacol ; 22(6): 637-647, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30402024

ABSTRACT

Extra-hypothalamic growth hormone-releasing hormone (GHRH) plays an important role in reproduction. To study the treatment effect of Grin (a novel hGHRH homodimer), the infertility models of 85 male Chinese hamsters were established by intraperitoneally injecting 20 mg/kg of cyclophosphamide once in a week for 5 weeks and the treatment with Grin or human menopausal gonadotropin (hMG) as positive control was evaluated by performing a 3-week mating experiment. 2-8 mg/kg of Grin and 200 U/kg of hMG showed similar effect and different pathological characteristics. Compared to the single cyclophosphamide group (0%), the pregnancy rates (H-, M-, L-Grin 26.7, 30.8, 31.3%, and hMG 31.3%) showed significant difference, but there was no difference between the hMG and Grin groups. The single cyclophosphamide group presented loose tubules with pathologic vacuoles and significant TUNEL positive cells. Grin induced less weight of body or testis, compactly aligned tubules with little intra-lumens, whereas hMG caused more weight of body or testis, enlarging tubules with annular clearance. Grin presented a dose-dependent manner or cell differentiation-dependentincrease in testicular GHRH receptor, and did not impact the levels of blood and testicular GH, testosterone. Grin promotes fertility by proliferating and differentiating primitive cells through up-regulating testicular GHRH receptor without triggering GH secretion, which might solve the etiology of oligoasthenozoospermia.

4.
Eur J Pharm Sci ; 117: 341-350, 2018 May 30.
Article in English | MEDLINE | ID: mdl-29526766

ABSTRACT

Extra-hypothalamic growth hormone-releasing hormone (GHRH) plays an important role in infertility. The female infertility models were formed by intraperitoneally injecting cyclophosphamide in 5-week-old Chinese hamster once in a week for 5 weeks. All the models mated with healthy male hamster in the ratio of 1:1 in the experimental 6-8th week and the couples were separated to breed in the 9-10th week. 20 mg/kg of cyclophosphamide induced temporary interference of reproduction and did not cause significant difference in the weight of body, bilateral ovaries, or liver. By intramuscularly injecting twice in a week during the experimental 4-10th week, 2, 4, 8 mg/kg of Grin induced 30, 42.9, 60% of total pregnancy rates in a dose-dependent manner whereas 200 U/kg of hMG induced 50% of total pregnancy rates. The single cyclophosphamide dose caused strongly eosinophilic ovarian cells, scattered early follicles, many atretic follicles, and no corpora luteum was observed. The hMG group individually presents many follicles at all levels, especially secondary ones in the ovarian cortex and medulla. Much of loose connective tissue, vacuoles, and sparse interstitial cells distribute in the medulla. Grin induced many follicles at all dose levels and corpora lutea in the cortex, and the compactly aligned interstitial cells occurred in the whole ovarian tissue. The less TUNEL staining and higher expression of ki67 showed the proliferation and protection effect of Grin on ovarian cells. Grin obviously promotes fertility by up-regulating ovarian GHRH receptor and strengthening the development and maturation of follicles without triggering central and ovarian GH secretion.


Subject(s)
Fertility Agents, Female/administration & dosage , Fertility/drug effects , Growth Hormone-Releasing Hormone/administration & dosage , Infertility, Female/drug therapy , Ovarian Follicle/drug effects , Ovary/drug effects , Receptors, Neuropeptide/agonists , Receptors, Pituitary Hormone-Regulating Hormone/agonists , Animals , Cricetulus , Cyclophosphamide , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Growth Hormone/metabolism , Growth Hormone-Releasing Hormone/analogs & derivatives , Infertility, Female/chemically induced , Infertility, Female/metabolism , Infertility, Female/physiopathology , Injections, Intramuscular , Male , Ovarian Follicle/metabolism , Ovarian Follicle/physiopathology , Ovary/metabolism , Ovary/physiopathology , Pregnancy , Pregnancy Rate , Receptors, Neuropeptide/metabolism , Receptors, Pituitary Hormone-Regulating Hormone/metabolism , Signal Transduction/drug effects , Time Factors , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...